286 related articles for article (PubMed ID: 34301810)
1. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; Georges S; Ellers-Lenz B; Shah P; Güzel G; Nghiem P
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301810
[TBL] [Abstract][Full Text] [Related]
2. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
3. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
5. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
[TBL] [Abstract][Full Text] [Related]
6. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
[TBL] [Abstract][Full Text] [Related]
7. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
Verschraegen CF; Jerusalem G; McClay EF; Iannotti N; Redfern CH; Bennouna J; Chen FL; Kelly K; Mehnert J; Morris JC; Taylor M; Spigel D; Wang D; Grote HJ; Zhou D; Munshi N; Bajars M; Gulley JL
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907924
[TBL] [Abstract][Full Text] [Related]
9. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
10. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.
Grignani G; Chiarion Sileni V; Pinto C; Depenni R; Fazio N; Galli L; Giuffrida D; Carnaghi C; Ciliberto D; Corsi DC; Queirolo P; Benincasa E; Venturini F; Fazzi G; Costa N; Ascierto PA
J Transl Med; 2021 Feb; 19(1):70. PubMed ID: 33588870
[TBL] [Abstract][Full Text] [Related]
11. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
[TBL] [Abstract][Full Text] [Related]
12. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
Walker JW; Lebbé C; Grignani G; Nathan P; Dirix L; Fenig E; Ascierto PA; Sandhu S; Munhoz R; Benincasa E; Flaskett S; Reed J; Engelsberg A; Hariharan S; Kasturi V
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269140
[TBL] [Abstract][Full Text] [Related]
14. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker AI; Burgess MA; Hanks BA; Olencki T; Margolin K; Lundgren LM; Soni A; Ramchurren N; Church C; Park SY; Shinohara MM; Salim B; Taube JM; Bird SR; Ibrahim N; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
J Clin Oncol; 2019 Mar; 37(9):693-702. PubMed ID: 30726175
[TBL] [Abstract][Full Text] [Related]
15. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort.
Levy S; Aarts MJB; Eskens FALM; Keymeulen KBMI; Been LB; Grünhagen D; van Akkooi A; Jalving M; Tesselaar MET
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948651
[TBL] [Abstract][Full Text] [Related]
16. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study.
Bhatia S; Nghiem P; Veeranki SP; Vanegas A; Lachance K; Tachiki L; Chiu K; Boller E; Bharmal M
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981787
[TBL] [Abstract][Full Text] [Related]
17. A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
Chang WC; Lin AY; Hsu JC; Wu CE; Goh C; Chou P; Kuo K; Chang A; Palencia R
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1399. PubMed ID: 33934577
[TBL] [Abstract][Full Text] [Related]
18. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
20. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]